<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04487925</url>
  </required_header>
  <id_info>
    <org_study_id>B6702020000326</org_study_id>
    <nct_id>NCT04487925</nct_id>
  </id_info>
  <brief_title>A Randomized Comparison of One Controlled Ovarian Stimulation With Corifollitropin Alfa Versus up to Three Modified Natural Cycles in Expected and Established Poor Responders</brief_title>
  <acronym>MONACO</acronym>
  <official_title>A Randomized Comparison of One Controlled Ovarian Stimulation With Corifollitropin Alfa Versus up to Three Modified Natural Cycles in Expected and Established Poor Responders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, single center, phase 3 controlled trial. The study will
      compare the efficacy of two different strategies for the management of predicted low
      prognosis patients under stimulation for IVF/ICSI: up to three MNC cycles (group 1) versus a
      single GnRH antagonist CFA (group 2).

      Our primary endpoint is the amount of good quality blastocyst.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of good quality blastocysts</measure>
    <time_frame>On fifth day of embryonal development</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total number of blastocysts</measure>
    <time_frame>On fifth day of embryonal development</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>cumulative ongoing pregnancy rate</measure>
    <time_frame>7 weeks of gestation</time_frame>
    <description>cumulative ongoing pregnancy rate at 7 weeks of gestation , confirmed by ultrasound.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">208</enrollment>
  <condition>Ovarian Reserve</condition>
  <condition>Poor Responders</condition>
  <condition>IVF</condition>
  <arm_group>
    <arm_group_label>Intervention group: up to 3 modified natural cycles</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive up to 3 modified natural cycles in stead of a conventional ovarian hyperstimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group: conventional ovarian stimulation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive a conventional ovarian stimulation with corifollitropin alfa.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Modified natural cycle</intervention_name>
    <description>Patients will receive up to three modified natural cycles instead of conventional ovarian hyperstimulation</description>
    <arm_group_label>Intervention group: up to 3 modified natural cycles</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent form (ICF) dated and signed.

          -  Age ≥18 and &lt;45 years-old.

          -  Body Mass Index (BMI) ≥18.5 Kg/m² and &lt;35 Kg/m².

          -  Regular menstrual cycles (between 21 and 35 days).

          -  Two ovaries present.

          -  Current pregnancy-wish.

          -  Poor responders as defined according to the POSEIDON criteria:

        POSEIDON Group 3: patients &lt; 35 years with poor ovarian reserve pre-stimulation parameters
        (AFC &lt;5 or AMH &lt;1.2 ng/mL); POSEIDON Group 4: patients ≥35 years with poor ovarian reserve
        pre-stimulation parameters (AFC &lt;5 or AMH &lt;1.2 ng/mL).

        Exclusion Criteria:

          -  Simultaneous participation in another clinical study.

          -  Untreated and uncontrolled thyroid dysfunction.

          -  Tumors of the ovary, breast, uterus, pituitary or hypothalamus.

          -  Abnormal (not menstrual) vaginal bleeding without a known/diagnosed cause.

          -  Ovarian cysts or enlarged ovaries.

          -  Malformations of the reproductive organs.

          -  Current use of oral contraceptives, anti-psychotics, anti-epileptics or chemotherapy.

          -  Previous antibiotic hypersensitivity reactions (streptomycin and/or neomycin).

          -  Patients who undergo preimplantation genetic testing (PGT), fertility preservation or
             oocyte donation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dominic Stoop, PhD</last_name>
    <phone>+32 09/332 49 03</phone>
    <email>arg.studies@uzgent.be</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

